Status and phase
Conditions
Treatments
About
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile-infected recipient, and has long been a successful approach to recurrent/refractory C. difficile. The purpose of this project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. This study will evaluate the safety and secondarily the efficacy of an inoculum administered by frozen orally-administered capsules.
Subjects with recurrent/relapsing C. difficile infection will receive FMT via oral capsules
The primary endpoint is assessment of safety as measured by clinical events (GI, procedural, systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C. difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a normal bowel status for the individual. Secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion criteria
Patients with refractory, recurrent or relapsing C. difficile infection (CDI) defined as EITHER:
Willingness to accept risk of unrelated donor stool
Age 7 and above. Seven is chosen as a lower limit based upon the legal age of assent. Based on the literature, most children aged 7 and above can be taught to swallow even large capsules through simple coaching techniques
Able to consent for self, or parental assent/child assent as age appropriate
Exclusion criteria
Delayed gastric emptying syndrome
Known chronic aspiration
Swallowing dysfunction or oral-motor dyscoordination.
Inability or unwillingness to swallow multiple large capsules
Pregnant women
Patients with an acute illness unrelated to CDI or an acute exacerbation of underlying comorbid condition
Patients with comorbidities associated with increased risk of serious infection following bacterial translocation, including but not limited to:
Patients with a history of significant allergy to foods not excluded from the donor diet
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal